Discrepancy between in vitro and in vivo antifungal activity of albendazole

T. C. Hardin, L. K. Najvar, J. Rizzo, A. W. Fothergill, M. G. Rinaldi, J. R. Graybill

Research output: Contribution to journalArticle

Abstract

Albendazole has in vitro activity against Cryptococcuss neoformans and reduced in vitro activity for albendazole when compared with Candida albicans. The major metabolite of albendazole, albendazole sulphoxide showed no in vitro activity against isolates of either fungus. Immunocompetent mice infected intravenously (IV) with C. albicans were treated with albendazole doses of 20-600 mg kg-1 per day in noble agar or sesame oil for per oral (PO) administration, or 80 mg kg-1 per day in DMSO for intraperitoneal (IP) and IV administration for 10 days, and were observed for survival. Mice infected with C. neoformans intracranially received albendazole in daily doses of 600 mg kg-1 prepared in DMSO (IP) or peanut butter/rat chow (PO) for 10 days and were observed for survival. Mortality was not different between the treated and control animals in any study. Plasma samples from uninfected mice dosed with similar formulations and doses of albendazole were analysed by HPLC for albendazole and albendazole sulphoxide. No albendazole could be detected in any sample, while concentrations of albendazole sulphoxide (286-8697 ng ml-1) were observed in all samples. These data suggest that the absence of in vivo activity for albendazole is due to rapid conversion to the inactive albendazole sulphoxide metabolite.

Original languageEnglish (US)
Pages (from-to)153-158
Number of pages6
JournalJournal of Medical and Veterinary Mycology
Volume35
Issue number3
StatePublished - 1997

Fingerprint

Albendazole
Dimethyl Sulfoxide
Candida albicans
Sesame Oil
In Vitro Techniques
Butter
Agar
Oral Administration
Fungi
High Pressure Liquid Chromatography
Mortality
albendazole sulfoxide

Keywords

  • Albendazole
  • Antifungal
  • Candida albicans
  • Cryptococcus neoformans

ASJC Scopus subject areas

  • Microbiology

Cite this

Hardin, T. C., Najvar, L. K., Rizzo, J., Fothergill, A. W., Rinaldi, M. G., & Graybill, J. R. (1997). Discrepancy between in vitro and in vivo antifungal activity of albendazole. Journal of Medical and Veterinary Mycology, 35(3), 153-158.

Discrepancy between in vitro and in vivo antifungal activity of albendazole. / Hardin, T. C.; Najvar, L. K.; Rizzo, J.; Fothergill, A. W.; Rinaldi, M. G.; Graybill, J. R.

In: Journal of Medical and Veterinary Mycology, Vol. 35, No. 3, 1997, p. 153-158.

Research output: Contribution to journalArticle

Hardin, TC, Najvar, LK, Rizzo, J, Fothergill, AW, Rinaldi, MG & Graybill, JR 1997, 'Discrepancy between in vitro and in vivo antifungal activity of albendazole', Journal of Medical and Veterinary Mycology, vol. 35, no. 3, pp. 153-158.
Hardin TC, Najvar LK, Rizzo J, Fothergill AW, Rinaldi MG, Graybill JR. Discrepancy between in vitro and in vivo antifungal activity of albendazole. Journal of Medical and Veterinary Mycology. 1997;35(3):153-158.
Hardin, T. C. ; Najvar, L. K. ; Rizzo, J. ; Fothergill, A. W. ; Rinaldi, M. G. ; Graybill, J. R. / Discrepancy between in vitro and in vivo antifungal activity of albendazole. In: Journal of Medical and Veterinary Mycology. 1997 ; Vol. 35, No. 3. pp. 153-158.
@article{e2e9df68f4bd478883abbac70596b457,
title = "Discrepancy between in vitro and in vivo antifungal activity of albendazole",
abstract = "Albendazole has in vitro activity against Cryptococcuss neoformans and reduced in vitro activity for albendazole when compared with Candida albicans. The major metabolite of albendazole, albendazole sulphoxide showed no in vitro activity against isolates of either fungus. Immunocompetent mice infected intravenously (IV) with C. albicans were treated with albendazole doses of 20-600 mg kg-1 per day in noble agar or sesame oil for per oral (PO) administration, or 80 mg kg-1 per day in DMSO for intraperitoneal (IP) and IV administration for 10 days, and were observed for survival. Mice infected with C. neoformans intracranially received albendazole in daily doses of 600 mg kg-1 prepared in DMSO (IP) or peanut butter/rat chow (PO) for 10 days and were observed for survival. Mortality was not different between the treated and control animals in any study. Plasma samples from uninfected mice dosed with similar formulations and doses of albendazole were analysed by HPLC for albendazole and albendazole sulphoxide. No albendazole could be detected in any sample, while concentrations of albendazole sulphoxide (286-8697 ng ml-1) were observed in all samples. These data suggest that the absence of in vivo activity for albendazole is due to rapid conversion to the inactive albendazole sulphoxide metabolite.",
keywords = "Albendazole, Antifungal, Candida albicans, Cryptococcus neoformans",
author = "Hardin, {T. C.} and Najvar, {L. K.} and J. Rizzo and Fothergill, {A. W.} and Rinaldi, {M. G.} and Graybill, {J. R.}",
year = "1997",
language = "English (US)",
volume = "35",
pages = "153--158",
journal = "Medical Mycology",
issn = "1369-3786",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Discrepancy between in vitro and in vivo antifungal activity of albendazole

AU - Hardin, T. C.

AU - Najvar, L. K.

AU - Rizzo, J.

AU - Fothergill, A. W.

AU - Rinaldi, M. G.

AU - Graybill, J. R.

PY - 1997

Y1 - 1997

N2 - Albendazole has in vitro activity against Cryptococcuss neoformans and reduced in vitro activity for albendazole when compared with Candida albicans. The major metabolite of albendazole, albendazole sulphoxide showed no in vitro activity against isolates of either fungus. Immunocompetent mice infected intravenously (IV) with C. albicans were treated with albendazole doses of 20-600 mg kg-1 per day in noble agar or sesame oil for per oral (PO) administration, or 80 mg kg-1 per day in DMSO for intraperitoneal (IP) and IV administration for 10 days, and were observed for survival. Mice infected with C. neoformans intracranially received albendazole in daily doses of 600 mg kg-1 prepared in DMSO (IP) or peanut butter/rat chow (PO) for 10 days and were observed for survival. Mortality was not different between the treated and control animals in any study. Plasma samples from uninfected mice dosed with similar formulations and doses of albendazole were analysed by HPLC for albendazole and albendazole sulphoxide. No albendazole could be detected in any sample, while concentrations of albendazole sulphoxide (286-8697 ng ml-1) were observed in all samples. These data suggest that the absence of in vivo activity for albendazole is due to rapid conversion to the inactive albendazole sulphoxide metabolite.

AB - Albendazole has in vitro activity against Cryptococcuss neoformans and reduced in vitro activity for albendazole when compared with Candida albicans. The major metabolite of albendazole, albendazole sulphoxide showed no in vitro activity against isolates of either fungus. Immunocompetent mice infected intravenously (IV) with C. albicans were treated with albendazole doses of 20-600 mg kg-1 per day in noble agar or sesame oil for per oral (PO) administration, or 80 mg kg-1 per day in DMSO for intraperitoneal (IP) and IV administration for 10 days, and were observed for survival. Mice infected with C. neoformans intracranially received albendazole in daily doses of 600 mg kg-1 prepared in DMSO (IP) or peanut butter/rat chow (PO) for 10 days and were observed for survival. Mortality was not different between the treated and control animals in any study. Plasma samples from uninfected mice dosed with similar formulations and doses of albendazole were analysed by HPLC for albendazole and albendazole sulphoxide. No albendazole could be detected in any sample, while concentrations of albendazole sulphoxide (286-8697 ng ml-1) were observed in all samples. These data suggest that the absence of in vivo activity for albendazole is due to rapid conversion to the inactive albendazole sulphoxide metabolite.

KW - Albendazole

KW - Antifungal

KW - Candida albicans

KW - Cryptococcus neoformans

UR - http://www.scopus.com/inward/record.url?scp=0030790946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030790946&partnerID=8YFLogxK

M3 - Article

C2 - 9229330

VL - 35

SP - 153

EP - 158

JO - Medical Mycology

JF - Medical Mycology

SN - 1369-3786

IS - 3

ER -